QURE - uniQure N.V.
NASDAQ
->
Healthcare
->
Biotechnology
Amsterdam,
Netherlands
Type: Equity
QURE price evolution
QURE
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $287.88 | $243.06 | $241.36 | |
| Short term investments | $236.55 | $312.62 | $376.53 | |
| Net receivables | $5.32 | $7.85 | $10.72 | $4.19 |
| Inventory | $7.67 | $12.02 | ||
| Total current assets | $464.14 | $591.97 | $596 | $651.85 |
| Long term investments | ||||
| Property, plant & equipment | $40.4 | $41.11 | $72.25 | $75.34 |
| Goodwill & intangible assets | $81.77 | $84.91 | $86.86 | |
| Total noncurrent assets | $138.88 | $174.05 | $179.84 | |
| Total investments | $236.55 | $312.62 | $376.53 | |
| Total assets | $645.81 | $730.85 | $770.05 | $831.69 |
| Current liabilities | ||||
| Accounts payable | $5.44 | $4.41 | $5.23 | $6.59 |
| Deferred revenue | ||||
| Short long term debt | $3.63 | $8 | $8.34 | |
| Total current liabilities | $71.27 | $80.47 | $63.47 | $73.67 |
| Long term debt | $477.8 | $530.82 | $534.5 | $524.31 |
| Total noncurrent liabilities | $553.27 | $559.82 | $550.34 | |
| Total debt | $534.44 | $542.5 | $532.65 | |
| Total liabilities | $589.99 | $633.74 | $623.3 | $624.02 |
| Shareholders' equity | ||||
| Retained earnings | -$1056.7 | -$1012.33 | -$956.03 | -$890.41 |
| Other shareholder equity | -$56.7 | -$56.32 | -$56.04 | -$53.55 |
| Total shareholder equity | $97.11 | $146.75 | $207.67 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $241.36 | $228.01 | $556.26 | $244.93 |
| Short term investments | $376.53 | $124.83 | ||
| Net receivables | $4.19 | $102.38 | $58.77 | $6.62 |
| Inventory | $12.02 | $6.92 | ||
| Total current assets | $651.85 | $476.77 | $628.24 | $258.91 |
| Long term investments | $39.98 | $2.75 | ||
| Property, plant & equipment | $75.34 | $83.26 | $69.08 | $58.41 |
| Goodwill & intangible assets | $86.86 | $84.36 | $90.32 | $3.9 |
| Total noncurrent assets | $179.84 | $228.19 | $180.94 | $81.48 |
| Total investments | $376.53 | $164.81 | $2.75 | |
| Total assets | $831.69 | $704.96 | $809.18 | $340.39 |
| Current liabilities | ||||
| Accounts payable | $6.59 | $10.98 | $2.5 | $3.77 |
| Deferred revenue | ||||
| Short long term debt | $8.34 | $8.38 | $5.77 | $5.52 |
| Total current liabilities | $73.67 | $75.92 | $36.76 | $27.33 |
| Long term debt | $524.31 | $102.79 | $129.95 | $66.02 |
| Total noncurrent liabilities | $550.34 | $153.04 | $176.64 | $69.16 |
| Total debt | $532.65 | $142.89 | $135.72 | $71.54 |
| Total liabilities | $624.02 | $228.96 | $213.4 | $96.49 |
| Shareholders' equity | ||||
| Retained earnings | -$890.41 | -$581.93 | -$455.14 | -$784.73 |
| Other shareholder equity | -$53.55 | -$58.29 | -$28.86 | $9.91 |
| Total shareholder equity | $207.67 | $476.01 | $595.78 | $243.91 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2.29 | $11.13 | $8.48 | $6.69 |
| Cost of revenue | $7.46 | $9.23 | $8.84 | |
| Gross Profit | $1.27 | $3.67 | -$0.74 | -$2.15 |
| Operating activities | ||||
| Research & development | $33.66 | $40.69 | $42.62 | |
| Selling, general & administrative | $15.77 | $13.94 | $17.49 | |
| Total operating expenses | $37.11 | $47.67 | $53.49 | $59.6 |
| Operating income | -$44.01 | -$54.23 | -$61.75 | |
| Income from continuing operations | ||||
| EBIT | -$39.19 | -$48.87 | -$54.46 | |
| Income tax expense | -$0.03 | $0.95 | $0.66 | $3.03 |
| Interest expense | -$4.18 | $16.16 | $16.1 | $15.71 |
| Net income | ||||
| Net income | -$44.38 | -$56.3 | -$65.62 | -$73.21 |
| Income (for common shares) | -$56.3 | -$65.62 | -$73.21 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $15.84 | $106.48 | $524 | $37.51 |
| Cost of revenue | $13.63 | $3.34 | $24.98 | |
| Gross Profit | $2.21 | $103.14 | $499.03 | $37.51 |
| Operating activities | ||||
| Research & development | $214.86 | $197.59 | $143.55 | $122.4 |
| Selling, general & administrative | $74.59 | $55.06 | $56.29 | $42.58 |
| Total operating expenses | $285.09 | $253.47 | $200.71 | $166.28 |
| Operating income | -$282.87 | -$150.33 | $298.31 | -$128.77 |
| Income from continuing operations | ||||
| EBIT | -$265 | -$116.56 | $340.28 | -$137.62 |
| Income tax expense | $1.92 | -$1.47 | $3.22 | -$16.42 |
| Interest expense | $41.56 | $11.7 | $7.47 | $3.83 |
| Net income | ||||
| Net income | -$308.48 | -$126.79 | $329.59 | -$125.02 |
| Income (for common shares) | -$308.48 | -$126.79 | $329.59 | -$125.02 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$56.3 | -$65.62 | -$73.21 | |
| Operating activities | ||||
| Depreciation | $2.67 | $2.63 | $4.19 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $6.88 | $7.19 | $7.04 | |
| Total cash flows from operations | -$32.71 | -$60.58 | -$49.54 | |
| Investing activities | ||||
| Capital expenditures | -$0.6 | -$2.34 | -$2.04 | |
| Investments | $78.54 | $66.33 | $61.6 | |
| Total cash flows from investing | $189.59 | $77.94 | $63.98 | $59.56 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.05 | $0.05 | ||
| Net borrowings | ||||
| Total cash flows from financing | -$52.97 | $0.05 | $0.05 | |
| Effect of exchange rate | $1.8 | -$0.47 | -$1.73 | $1.84 |
| Change in cash and equivalents | $8.54 | $44.81 | $1.69 | $11.91 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$308.48 | -$126.79 | $329.59 | -$125.02 |
| Operating activities | ||||
| Depreciation | $11.9 | $8.54 | $7.3 | $10.65 |
| Business acquisitions & disposals | -$1.9 | -$49.95 | ||
| Stock-based compensation | $35.09 | $34.2 | $25.64 | $21.83 |
| Total cash flows from operations | -$145.93 | -$145.06 | $287.96 | -$134.83 |
| Investing activities | ||||
| Capital expenditures | -$7.15 | -$17.69 | -$17.44 | -$7.27 |
| Investments | -$198.53 | -$163.15 | ||
| Total cash flows from investing | -$205.69 | -$182.73 | -$67.39 | -$9.48 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.31 | $1.45 | $32.36 | $7.44 |
| Net borrowings | $370.06 | $62.49 | ||
| Total cash flows from financing | $362.72 | $1.45 | $94.86 | $7.44 |
| Effect of exchange rate | $2.27 | -$1.83 | -$3.76 | $3.82 |
| Change in cash and equivalents | $13.37 | -$328.18 | $311.67 | -$133.05 |
News
Fundamentals
| Market cap | $3.44B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 48.74M |
| Revenue | $28.59M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$239.50M |
| Revenue Q/Q | 62.54% |
| Revenue Y/Y | -74.45% |
| P/E ratio | -14.37 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 120.35 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$4.91 |
|---|---|
| ROA | -32.17% |
| ROE | N/A |
| Debt/Equity | 3.00 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 6.51 |
| Quick ratio | N/A |